Abhishek A. Singh

Abhishek A. Singh

Auto-generated profile, based on publicly available information

Abhishek A. Singh

Department of Molecular Biology, Faculty of Science, Nijmegen Centre for Molecular Life Sciences, Radboud University, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2012 in Blood
Verified
Journal Article
Open access
PDF file
JMJ. H. A. Martens
J. H. A. Martens
AMAmit Mandoli
Amit Mandoli
FSFemke Simmer
Femke Simmer
BWBart-Jan Wierenga
Bart-Jan Wierenga
SSSadia Saeed
Sadia Saeed
HSHendrik G. Stunnenberg
Hendrik G. Stunnenberg
ERG and FLI1 are closely related members of the ETS family of transcription factors and have been identified as essential factors for the function and maintenance of normal hematopoietic stem cells. Here genome-wide analysis revealed that both ERG and FLI1 occupy similar genomic regions as AML1-ETO in t(8;21) AMLs and identified ERG/FLI1 as proteins that facilitate binding of oncofusion protein complexes. In addition, we demonstrate that ERG and FLI1 bind the RUNX1 promoter and that shRNA-mediated silencing of ERG leads to reduced expression of RUNX1 and AML1-ETO, consistent with a role of ERG in transcriptional activation of these proteins. Finally, we identify H3 acetylation as the epigenetic mark preferentially associated with ETS factor binding. This intimate connection between ERG/FLI1 binding and H3 acetylation implies that one of the molecular strategies of oncofusion proteins, such as AML1-ETO and PML-RAR-α, involves the targeting of histone deacetylase activities to ERG/FLI1 bound hematopoietic regulatory sites. Together, these results highlight the dual importance of ETS factors in t(8;21) leukemogenesis, both as transcriptional regulators of the oncofusion protein itself as well as proteins that facilitate AML1-ETO binding.

7 September 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CNchandan kadur nagaraju
chandan kadur nagaraju
EDEef Dries
Eef Dries
NPNatasa Popovic
Natasa Popovic
ASAbhishek A. Singh
Abhishek A. Singh
PHPeter Haemers
Peter Haemers
RDRonald B. Driesen
Ronald B. Driesen
Fibroblast (Fb) differentiation and interstitial fibrosis contribute to cardiac remodeling and loss of function after myocardial infarction (MI). We investigated regional presence and regulation of fibrosis in a pig MI model. In vivo analysis of regional function and perfusion defined three regions: the scar, the myocardium adjacent to the scar (MIadjacent, reduced function, reduced perfusion reserve), and the remote myocardium (MIremote, minimal functional deficit, maintained perfusion). Interstitial and perivascular fibrosis, and increase of collagen type I, was only observed in the MIadjacent. Fb activated protein-alpha (FAP-α) was enriched in MIadjacent compared to MIremote. TGF-β1, which triggers Fb differentiation, was upregulated in both MIadjacent and MIremote, whereas lysyl oxidase, a regulator of collagen cross-linking, and the proteoglycans decorin and biglycan were only increased in the MIadjacent. Fb isolated and cultured for 4 days had myoFb characteristics with little difference between MIremote and MIadjacent, although RNA sequencing revealed differences in gene expression profiles. Fbs from all regions maintained proliferative capacity, and induced contraction of 3-D collagen matrices but scar myoFb was more effective. These data suggest that after MI, signaling through TGF-β1, possibly related to increased mechanical load, drives Fb activation throughout the left ventricle while regional signaling determines further maturation and extracellular matrix remodeling after MI.

1 November 2016 in Cell Reports
Verified
Journal Article
Open access
AMAmit Mandoli
Amit Mandoli
ASAbhishek A. Singh
Abhishek A. Singh
KPKoen H.M. Prange
Koen H.M. Prange
ETEsther Tijchon
Esther Tijchon
MOMarjolein Oerlemans
Marjolein Oerlemans
JMJ. H. A. Martens
J. H. A. Martens
The t(8;21) acute myeloid leukemia (AML)-associated oncoprotein AML1-ETO disrupts normal hematopoietic differentiation. Here, we have investigated its effects on the transcriptome and epigenome in t(8,21) patient cells. AML1-ETO binding was found at promoter regions of active genes with high levels of histone acetylation but also at distal elements characterized by low acetylation levels and binding of the hematopoietic transcription factors LYL1 and LMO2. In contrast, ERG, FLI1, TAL1, and RUNX1 bind at all AML1-ETO-occupied regulatory regions, including those of the AML1-ETO gene itself, suggesting their involvement in regulating AML1-ETO expression levels. While expression of AML1-ETO in myeloid differentiated induced pluripotent stem cells (iPSCs) induces leukemic characteristics, overexpression increases cell death. We find that expression of wild-type transcription factors RUNX1 and ERG in AML is required to prevent this oncogene overexpression. Together our results show that the interplay of the epigenome and transcription factors prevents apoptosis in t(8;21) AML cells.

18 October 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KTKaty Teo
Katy Teo
LGLaura Gómez-Cuadrado
Laura Gómez-Cuadrado
MTMilou Tenhagen
Milou Tenhagen
ABAdam Byron
Adam Byron
MRMax Rätze
Max Rätze
PDPatrick W. B. Derksen
Patrick W. B. Derksen
Despite the fact that loss of E-cadherin is causal to the development and progression of invasive lobular carcinoma (ILC), options to treat this major breast cancer subtype are limited if tumours develop resistance to anti-oestrogen treatment regimens. This study aimed to identify clinically targetable pathways that are aberrantly active downstream of E-cadherin loss in ILC. Using a combination of reverse-phase protein array (RPPA) analyses, mRNA sequencing, conditioned medium growth assays and CRISPR/Cas9-based knock-out experiments, we demonstrate that E-cadherin loss causes increased responsiveness to autocrine growth factor receptor (GFR)-dependent activation of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/Akt signalling. Autocrine activation of GFR signalling and its downstream PI3K/Akt hub was independent of oncogenic mutations in PIK3CA, AKT1 or PTEN. Analyses of human ILC samples confirmed growth factor production and pathway activity. Pharmacological inhibition of Akt using AZD5363 or MK2206 resulted in robust inhibition of cell growth and survival of ILC cells, and impeded tumour growth in a mouse ILC model. Because E-cadherin loss evokes hypersensitisation of PI3K/Akt activation independent of oncogenic mutations in this pathway, we propose clinical intervention of PI3K/Akt in ILC based on functional E-cadherin inactivation, irrespective of activating pathway mutations.

24 December 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
ASAbhishek A. Singh
Abhishek A. Singh
AMAmit Mandoli
Amit Mandoli
KPKoen H.M. Prange
Koen H.M. Prange
MLMarko Laakso
Marko Laakso
JMJ. H. A. Martens
J. H. A. Martens
AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis

1 August 2014 in Experimental Hematology
Verified
Journal Article
Closed access
KPKoen H.M. Prange
Koen H.M. Prange
ASAbhishek A. Singh
Abhishek A. Singh
JMJ. H. A. Martens
J. H. A. Martens